New Immune Design Data Highlights Expanded Product Potential Of ZVex® Platform At The 2016 SITC Annual Meeting

SEATTLE and SOUTH SAN FRANCISCO, Ca., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Immune Design, a clinical-stage immunotherapy company focused on oncology, today announced new preclinical data demonstrating the ability of its ZVex discovery platform to induce immune responses to multiple antigens co-delivered selectively to dendritic cells in vivo. In addition, the company will present data on an alternate prime boost approach than that currently under investigation in Phase 2 studies.  These data are being presented at the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Conference taking place Nov. 9-13, 2016 in National Harbor, Maryland.

"This advancement of the ZVex platform enables the expression of potentially any combination of full-length conserved tumor antigens, neo-epitopes and immune enhancers from a single preparation, without resulting in antigen competition," said Jan ter Meulen, MD, PhD, Chief Scientific Officer at Immune Design. "This allows us to target a wide range of tumors with either off-the-shelf products or fully personalized therapies, thereby representing a potentially significant step forward in the evolution of our next-generation product development scope."

Presentations

Immune Design scientists present data showing that immunization with multi-genome ZVex vectors expressing NY-ESO-1, MAGE-A3 and MAGE-A10 results in consistent induction of polyfunctional CD8 T cells against all three antigens and demonstrates significant improvement of immunogenicity by co-expression of the cytokine IL-12 . Immune responses were as high as, or higher, than those obtained by combining individually manufactured vectors, demonstrating the versatility and potency of this multi-antigen ZVex approach.

In a second presentation highlighting an alternate ZVex-based prime boost, Immune Design scientists present data demonstrating in murine B16 and metastatic C26 colon carcinoma models that priming with a ZVex vector carrying the RNA for a tumor-associated antigen (TAA) and boosting with an adenoviral vector (Ad5) encoding the same antigen resulted in increased frequency of TAA-specific T cells and improved anti-tumor efficacy over a prime-boost regimen with ZVex alone.

If you liked this article you might like

5 Stocks Insiders Love Right Now

7 Stocks Spiking on Big Volume

7 Stocks Making Big Moves on Unusual Volume

5 Stocks Insiders Love Right Now